Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
I received the link to the Review via email. Key statement about the key profit-maker for the Quarter: "SPARC is arguably the most aggressive holding admitted to the portfolio since the Fund’s inception..." http://www.sunpharma.in/
